EWOLUTION Risk Model (Watchman Outcomes) Calculator

EWOLUTION Risk Model (Watchman Outcomes): Comprehensive Explanation and Clinical Context This calculator implements the risk stratification described from the EWOLUTION registry of patients undergoing percutaneous left atrial appendage occlusion (LAAO) with the Watchman device. In a patient-level analysis of 1,020 all-comers, six baseline variables independently predicted all-cause mortality at two years: older age, heart failure, vascular disease, valvular disease, abnormal liver function, and abnormal renal function. For practical use, age was dichotomized at 76 years and combined with the other five comorbidities into a simple count.

The observed two-year mortality increased stepwise with the number of risk factors: approximately 5.6–5.7% with 0–1 factor, 14.4% with 2, ~30–33% with 3–4, and ~46% with ≥5 factors. This pattern helps clinicians gauge whether the competing risk of early death could offset the long-term stroke-prevention benefits and cost-effectiveness of LAAO. Model scope and limitations.

The EWOLUTION analysis provides hazard ratios and a pragmatic grouping by the number of risk factors rather than a fully specified, validated point score with an absolute-risk equation. Consequently, this tool reports the published group-level mortality observed in EWOLUTION, not an individualized probability from a calibrated Cox model. Notably, no internal or external validation of a formal risk score was performed in the publication, and several definitions were based on investigator assessment; for example, abnormal renal function in EWOLUTION included serum creatinine ≥200 µmol/L or dialysis/renal transplant.

As devices (e.g., Watchman FLX/FLX Pro) and patient selection have evolved, contemporary cohorts may have lower absolute mortality than the original EWOLUTION era; interpret results in present-day context and alongside frailty, competing risks, and guideline recommendations. Clinical interpretation summary. Patients with ≤1 risk factor generally exhibited low two-year mortality (<6%), supporting the likelihood of realizing long-term LAAO benefits.

Those with 2 factors had intermediate risk (~14%), warranting individualized judgment. Patients with ≥3 factors—especially ≥5—had high two-year mortality (~30–46%), signaling substantial competing risk that may diminish net benefit from an invasive stroke-prevention strategy. Use this tool to inform shared decision-making, not to replace clinical expertise.